Stockscreener 앱 받기
9.69
1.82%
-0.18
시간 외 거래:
9.50
-0.19
-1.96%
전일 마감가:
$9.87
열려 있는:
$9.74
하루 거래량:
579.89K
Relative Volume:
0.61
시가총액:
$843.15M
수익:
-
순이익/손실:
$-106.81M
주가수익비율:
-2.926
EPS:
-3.3117
순현금흐름:
$-8.40M
1주 성능:
-8.50%
1개월 성능:
+13.33%
6개월 성능:
-10.86%
1년 성능:
-25.12%
1일 변동 폭
$9.60
$10.03
1주일 범위
$9.60
$11.13
52주 변동 폭
$5.1501
$16.73
이뮤놈 Stock (IMNM) Company Profile
명칭
Immunome Inc
전화
610-321-3700
주소
18702 N. CREEK PARKWAY, BOTHELL
IMNM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
9.69 | 910.15M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
이뮤놈 Stock (IMNM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Lake Street | Buy |
| 2024-11-08 | 개시 | Stephens | Overweight |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-04-30 | 개시 | JP Morgan | Overweight |
| 2024-04-15 | 개시 | Guggenheim | Buy |
| 2024-01-29 | 개시 | Leerink Partners | Outperform |
| 2023-12-19 | 개시 | Wedbush | Outperform |
| 2021-10-29 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
이뮤놈 주식(IMNM)의 최신 뉴스
Will Immunome Inc. bounce back from current supportWeekly Price Target Forecast and Alerts - Newser
What makes Immunome Inc. stock attractive to long term investorsLong Term Stock Planner with Safety Checks - Newser
Immunome, Inc. (NASDAQ:IMNM) Revenue Estimates Upgraded by 73% - AInvest
Growth Investors: Industry Analysts Just Upgraded Their Immunome, Inc. (NASDAQ:IMNM) Revenue Forecasts By 73% - Yahoo Finance
How to forecast Immunome Inc. trends using time seriesDaily Trade Monitor with Pattern Alerts - Newser
Immunome 2025 Q2 Earnings Wider Net Loss Despite Revenue Surge - AInvest
New Product Launches: Will They Boost Immunome Inc. Stock in 2025Growth Focused Entry Plan Suggestions Issued - beatles.ru
JP Morgan Lowers Price Target for Immunome (IMNM) While Maintain - GuruFocus
Immunome 2025 Q2 Earnings Narrowed EPS Loss, 69.8% Revenue Growth - AInvest
Will Immunome Inc. stock recover after recent dropFree Consistent Gain Investment Strategies - Newser
What’s next for Immunome Inc. stock priceFree Secure Return Focused Investment Plan - Newser
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Immunome Advances Cancer Therapy Pipeline Amid Financial Loss - TipRanks
Does Immunome Inc. qualify in momentum factor screeningFree Triple Return Setup with Risk Control - Newser
Immunome earnings beat by $0.12, revenue topped estimates - Investing.com Canada
Immunome’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating - TipRanks
Immunome Q2 Earnings: Revenue $4.01M, Consensus $1.02M; Expects Cash to Fund Operations into 2027 - AInvest
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Immunome Reports Second Quarter 2025 Financial Results and Provi - GuruFocus
Detecting price anomalies in Immunome Inc. with AIFree Weekly Potential Breakout Stock List - Newser
How Immunome Inc. stock performs during market volatilityFree Momentum Based Equity Trading Plan - Newser
Can Immunome Inc. rally from current levelsStock Entry Point Planner with Volume Spike - Newser
Will Immunome Inc. continue its uptrendStock Market Trend and Pattern Analysis - Newser
What to do if you’re stuck in Immunome Inc.Real Stock Picks With Setup Verification - Newser
What earnings revisions data tells us about Immunome Inc.Trading Volume Spike and Reversal Analysis - Newser
What momentum shifts mean for Immunome Inc.Trade Flow Monitor with Volume Tracker - Newser
Will Immunome Inc. Stock Benefit from AI and Green Energy TrendsLow Risk High Confidence Watchlist Builder - Newser
What institutional investors are buying Immunome Inc. stockAchieve rapid portfolio growth with smart picks - Jammu Links News
How does Immunome Inc. compare to its industry peersCapitalize on stocks with high profit margins - Jammu Links News
What are Immunome Inc. company’s key revenue driversCapitalize on emerging industry trends - Jammu Links News
What is the risk reward ratio of investing in Immunome Inc. stockOutstanding capital returns - Jammu Links News
Is it the right time to buy Immunome Inc. stockInvest confidently with actionable market data - Jammu Links News
When is Immunome Inc. stock expected to show significant growthMaximize returns with effective portfolio management - Jammu Links News
Is Immunome Inc. stock overvalued or undervaluedRealize exceptional returns through smart trading - Jammu Links News
Immunome Inc. Stock Analysis and ForecastUnlock expert market analysis instantly - Jammu Links News
What is the dividend policy of Immunome Inc. stockBuild wealth faster with high-performing stocks - Jammu Links News
Why is Immunome Inc. stock attracting strong analyst attentionTriple-digit return opportunities - Jammu Links News
Why Immunome Inc. stock attracts strong analyst attentionReal Time Stock Movement Analysis Indicates Breakout - beatles.ru
Immunome Grants Inducement Awards to New Employees Under Nasdaq Rules, Prices Stock Options at $10.59. - AInvest
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Wedbush Reaffirms Buy Rating on Immunome with $21 Target - AInvest
이뮤놈 (IMNM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):